Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. EJE PRIZE 2018: A gut feeling about glucagon

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Association of maternal thyroid function with birthweight: a systematic review and individual-participant data meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Semen quality in hypogonadal acromegalic patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Gudmundur Johannsson
  • Ulla Feldt-Rasmussen
  • Ida Holme Håkonsson
  • Henrik Biering
  • Patrice Rodien
  • Shigeyuki Tahara
  • Andrew Toogood
  • Michael Højby Rasmussen
  • REAL 2 Study Group
Vis graf over relationer

OBJECTIVE: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative, developed for once-weekly administration. This study aimed to evaluate the safety of once-weekly somapacitan vs once-daily Norditropin®. Local tolerability and treatment satisfaction were also assessed.

DESIGN: 26-week randomized, controlled phase 3 safety and tolerability trial in six countries (Nbib2382939).

METHODS: Male or female patients aged 18-79 years with adult GH deficiency (AGHD), treated with once-daily GH for ≥6 months, were randomized to once-weekly somapacitan (n = 61) or once-daily Norditropin (n = 31) administered subcutaneously by pen. Both treatments were dose titrated for 8 weeks to achieve insulin-like growth factor I (IGF-I) standard deviation score (SDS) levels within the normal range, and then administered at a fixed dose. Outcome measures were adverse events (AEs), including injection site reactions; occurrence of anti-somapacitan/anti-GH antibodies and change in treatment satisfaction, assessed using the Treatment Satisfaction Questionnaire for Medication-9 (TSQM-9).

RESULTS: Mean IGF-I SDS remained between 0 and 2 SDS throughout the trial in both groups. AEs were mostly mild or moderate and transient in nature. The most common AEs were nasopharyngitis, headache and fatigue in both groups. More than 1500 somapacitan injections were administered and no clinically significant injection site reactions were reported. No anti-somapacitan or anti-GH antibodies were detected. The TSQM-9 score for convenience increased significantly more with somapacitan vs Norditropin (P = 0.0171).

CONCLUSIONS: In this 26-week trial in patients with AGHD, somapacitan was well tolerated and no safety issues were identified. Once-weekly somapacitan was reported to be more convenient than once-daily Norditropin.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind178
Udgave nummer5
Sider (fra-til)491-499
Antal sider9
ISSN0804-4643
DOI
StatusUdgivet - maj 2018

ID: 55074469